Ferraro, Daniela A.
Laudicella, Riccardo
Zeimpekis, Konstantinos
Mebert, Iliana
Müller, Julian
Maurer, Alexander
Grünig, Hannes
Donati, Olivio
Sapienza, Marcelo T.
Rueschoff, Jan H.
Rupp, Niels
Eberli, Daniel
Burger, Irene A. http://orcid.org/0000-0001-8029-8692
Funding for this research was provided by:
University of Zurich
Article History
Received: 24 August 2021
Accepted: 19 October 2021
First Online: 2 November 2021
Declarations
:
: This study was approved by the institutional review board (BASEC Nr: 2017–00016), was carried out following principles enunciated in the current version of the Declaration of Helsinki, and is registered in the international trial registry ClinicalTrials.gov (NCT03187990).
: Informed consent was obtained from all individual participants included in the study.
: All authors approved the manuscript and agree with its publication in the European Journal of Nuclear Medicine and Molecular Imaging.
: IAB has received research grants and speaker honorarium from GE Healthcare, research grants from Swiss Life, and speaker honorarium from Bayer Health Care and Astellas Pharma AG. NR has provided consultancy services (advisory board member) to F. Hoffmann-La Roche AG. All other authors declare no competing interests with this work. Funding sources had no involvement in study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.